c噩梦疗法短期有限目标明确最终成功

IF 2 4区医学 Q3 ONCOLOGY

Oncology Research and Treatment Pub Date : 2023-08-22 DOI:10.1159/000533717

{"title":"c噩梦疗法短期有限目标明确最终成功","authors":"","doi":"10.1159/000533717","DOIUrl":null,"url":null,"abstract":"information@karger.com www.karger.com bucil und Obinutuzumab (ClbO, n = 216) [3]. Eingeschlossen wurden unvorbehandelte unfitte CLL-Patient*innen mit Komorbiditäten (Gesamtscore der Cumulative Illness Rating Scale (CIRS) > 6 oder KreatininClearance < 70 ml/ min). Nach einer medianen Nachbeobachtungszeit von 76,4 Monaten war der Unterschied zwischen den beiden Behandlungsarmen hinsichtlich des progressionsfreien Überlebens (progression-free survival, PFS) – primärer Endpunkt der Studie – immer noch signifikant [2].","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"46 1","pages":"392 - 395"},"PeriodicalIF":2.0000,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CLL-Therapien: Zeitlich begrenzt und zielgerichtet, langfristig erfolgreich\",\"authors\":\"\",\"doi\":\"10.1159/000533717\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"information@karger.com www.karger.com bucil und Obinutuzumab (ClbO, n = 216) [3]. Eingeschlossen wurden unvorbehandelte unfitte CLL-Patient*innen mit Komorbiditäten (Gesamtscore der Cumulative Illness Rating Scale (CIRS) > 6 oder KreatininClearance < 70 ml/ min). Nach einer medianen Nachbeobachtungszeit von 76,4 Monaten war der Unterschied zwischen den beiden Behandlungsarmen hinsichtlich des progressionsfreien Überlebens (progression-free survival, PFS) – primärer Endpunkt der Studie – immer noch signifikant [2].\",\"PeriodicalId\":19543,\"journal\":{\"name\":\"Oncology Research and Treatment\",\"volume\":\"46 1\",\"pages\":\"392 - 395\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Research and Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000533717\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000533717","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

这一网站(www.karger.com) www.bucil和因纽安慰网站(cbo, n = 216)[3]。包括未经处理的癌症病人*包含共通性(累积的知识级别> 6或生物交换< 70毫升/ min)。经过第76.4个月的中期观察之后，你们治疗的对象在进退生存方面的差异依然显著[2]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

CLL-Therapien: Zeitlich begrenzt und zielgerichtet, langfristig erfolgreich

information@karger.com www.karger.com bucil und Obinutuzumab (ClbO, n = 216) [3]. Eingeschlossen wurden unvorbehandelte unfitte CLL-Patient*innen mit Komorbiditäten (Gesamtscore der Cumulative Illness Rating Scale (CIRS) > 6 oder KreatininClearance < 70 ml/ min). Nach einer medianen Nachbeobachtungszeit von 76,4 Monaten war der Unterschied zwischen den beiden Behandlungsarmen hinsichtlich des progressionsfreien Überlebens (progression-free survival, PFS) – primärer Endpunkt der Studie – immer noch signifikant [2].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncology Research and Treatment ONCOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.